CollabRx, Inc. (NASDAQ: CLRX) has announced a multi-year, non-exclusive agreement with Quest Diagnostics (NYSE: DGX), a provider of diagnostic information services related to medical annotation for new next-generation sequencing test services for cancer.
Under the agreement, Quest Diagnostics has the right to incorporate into clinical test reports for its next-generation sequencing cancer tests medical content, such as scientific literature, medical guidelines and published therapeutic protocols. The service was developed by CollabRx and customized for use by Quest Diagnostics.
The annotated content may help physicians better understand, through the database, the clinical significance of test results indicating the presence of one or more gene mutations. Quest will also have the right to incorporate the CollabRx content into clinical trials services performed on behalf of its pharmaceutical and other clients. Additional terms of the agreement were not disclosed.
CollabRx is a leader in cloud-based expert systems to inform healthcare decision-making, using information technology to aggregate and contextualize the world´s knowledge on genomics-based medicine with specific insights from the nation´s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.
Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company was founded in 1967 and is headquartered in Madison, New Jersey. The company´s website is at http://www.questdiagnostics.com.